^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NKG2DL-targeted CAR-T immunotherapy

    Related drugs:
    Apply
    Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors (NCT05976906)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    08/04/2023
    Initiation :
    05/23/2023
    Primary completion :
    05/01/2025
    Completion :
    09/01/2025
    IL2
    |
    cyclophosphamide • CNK-UT
    NKG2D CAR-NK & r/rAML (NCT05734898)
    Phase N/A
    Zhejiang University
    Recruiting
    Last update posted :
    03/03/2023
    Initiation :
    03/01/2023
    Primary completion :
    04/01/2024
    Completion :
    09/01/2024
    NKG2D
    |
    NKG2D CAR-NK cell therapy
    Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) (NCT05302037)
    Phase 1
    CytoMed Therapeutics Pte Ltd
    Not yet recruiting
    Last update posted :
    03/31/2022
    Initiation :
    04/01/2022
    Primary completion :
    03/01/2023
    Completion :
    12/01/2023
    NKG2D
    |
    CTM-N2D
    Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer (KEYNOTE-B79) (NCT04991948)
    Phase 1
    Celyad Oncology SA
    Recruiting
    Last update posted :
    03/09/2022
    Initiation :
    11/22/2021
    Primary completion :
    08/21/2023
    Completion :
    05/25/2038
    MSI
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CYAD-101